Pancreatic Cancer Research

ResearcherHiroshima UniversityActive in the last 2 years

Ryuta Shintakuya

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6277-9836; OpenAlex author ID A5091312302. Sources: OpenAlex.

Their work

Papers
11
Trials
0
Grants
0
Labs led
0
Collaborators
42
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 3 papers · 2024: 2 papers · 2025: 1 paper · 2026: 4 papers

Papers 11

  1. Duke Pancreatic Monoclonal Antigen Type 2 for Monitoring Carbohydrate Antigen 19-9 Nonexpressor Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2026.1810↗
  2. Survival Impact After Resection for Postoperative Recurrence or Metastasis of Pancreatic Ductal Adenocarcinoma Analyzed Using a Time-Dependent Cox Regression M… Co-author DOI 10.1002/jhbp.70054↗
  3. Independent Prognostic Value of Natural Tooth Count Versus Posterior Teeth Occlusion in Resected Pancreatic Cancer. Co-author DOI 10.1002/jhbp.70113↗
  4. Prognostic Impact of the Combined Use of CA19-9 and DUPAN-2 in Initially Unresectable Locally Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-026-20710-4↗
  5. Survival benefit of adjuvant therapy completion with early initiation for patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ags3.12898↗
  6. Long-term outcomes of neoadjuvant gemcitabine, nab-paclitaxel, and S1 (GAS) in borderline resectable pancreatic cancer with arterial contact: Results from a ph… Co-author DOI 10.1002/jhbp.1412↗
  7. Clinical Utility of the Combined Use of CA19-9 and DUPAN-2 in Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-024-15221-z↗
  8. Prognostic factor in patient with recurrent pancreatic adenocarcinoma. Co-author DOI 10.1007/s00423-023-03073-2↗
  9. Pathologic complete response following FOLFIRINOX and olaparib treatment for hepatic metastasized pancreatic ductal adenocarcinoma with a germline BRCA mutatio… Co-author DOI 10.1007/s12328-022-01741-2↗
  10. Increased plasma miR-370-3p expression in poor-outcome patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2023.10.019↗
  11. The high stromal SPARC expression is independently associated with poor survival of patients with resected pancreatic ductal adenocarcinoma treated with adjuva… Co-author DOI 10.1016/j.pan.2017.12.014↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kenichiro Uemura · 11 shared papers, 2018–2026 · strength 2.24
  2. Kenjiro Okada · 10 shared papers, 2023–2026 · strength 2.15
  3. Tatsuaki Sumiyoshi · 8 shared papers, 2023–2026 · strength 1.75
  4. Yoshiaki Murakami · 7 shared papers, 2018–2026 · strength 1.46
  5. Shin’ya Takahashi · 7 shared papers, 2018–2025 · strength 1.27
  6. Takumi Harada · 5 shared papers, 2023–2026 · strength 1.11
  7. Yasutaka Ishii · 5 shared papers, 2023–2026 · strength 1.04
  8. Kenta Baba · 4 shared papers, 2023–2025 · strength 0.81
  9. Shiro Oka · 2 shared papers, 2025–2026 · strength 0.51
  10. Yosuke Inoue · 2 shared papers, 2026 · strength 0.41
  11. So Yamaki · 2 shared papers, 2026 · strength 0.41
  12. Sohei Satoi · 2 shared papers, 2026 · strength 0.41
  13. Teiichi Sugiura · 2 shared papers, 2026 · strength 0.41
  14. Masamichi Mizuma · 2 shared papers, 2026 · strength 0.41
  15. Atsushi Oba · 2 shared papers, 2026 · strength 0.41
  16. Daisuke Hashimoto · 2 shared papers, 2026 · strength 0.41
  17. Daisuke Ban · 2 shared papers, 2026 · strength 0.41
  18. Katsuhisa Ohgi · 2 shared papers, 2026 · strength 0.41
  19. Nobuhiko Nakagawa · 2 shared papers, 2026 · strength 0.41
  20. Koetsu Inoue · 2 shared papers, 2026 · strength 0.41
  21. Michiaki Unno · 2 shared papers, 2026 · strength 0.41
  22. Satoshi Hirano · 2 shared papers, 2026 · strength 0.41
  23. Fuyuhiko Motoi · 2 shared papers, 2026 · strength 0.41
  24. Hiroyuki Otsuka · 2 shared papers, 2023 · strength 0.34
  25. Shinya Takahashi · 1 shared paper, 2026 · strength 0.30

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.